Catalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for TNX-102 SL in Acute Stress Reaction. The expected timing is based on the latest available company guidance and may change.
OASIS trial: 2/12/24 Cleared IND for Ph2. Sponsored by UNC & DoD. 3/20/25- Study initiation in H1 2025. 5/21/25- 1st patient dosed; topline data in H2 2026. 11/10/25:- Described the OASIS investigator-initiated study of TNX-102 SL for acute stress-related conditions funded by the DoD; no change to H2 2026 topline data guidance. 03/12/26:- OASIS trial ongoing; topline TNX-102 SL acute stress data still expected in H2 2026. 05/11/26:- OASIS investigator-initiated Ph2 ASD/ASR trial ongoing; topline TNX-102 SL data still expected in H2 2026. 08/10/26:- OASIS Ph2 topline data timing moved to Mid-2027.
Verification
Confirm timing and program details against the company announcement or filing.